Investigational drug · Phase 3
ELA026
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Secondary Hemophagocytic Lymphohistiocytosis (sHLH).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ELA026"
First trial start
2022
May 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ELA026", any sponsor or status.
Conditions studied
As listed on its trial records.
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Largest trials
Live from ClinicalTrials.gov: studies naming "ELA026" as an intervention, largest first.
- Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)Pivotal-lookingRecruiting
Electra Therapeutics Inc.Industry
NCT05416307 · 156 participants (planned) · Start May 19, 2022 · Primary completion Mar 2028
Drug: ELA026 · For: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 42 sites in all
Electra Therapeutics Inc.Industry
NCT05556863 · 91 participants · Start Oct 18, 2021 · Primary completion Nov 20, 2023
Drug: ELA026; ELA026 · For: Healthy Volunteers
Sites: Lincoln, Nebraska; Vienna, Austria
- A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)Recruiting
Electra Therapeutics Inc.Industry
NCT07465835 · 84 participants (planned) · Start Feb 17, 2026 · Primary completion Jun 2028
Drug: ELA026 · For: T Cell Malignancies
Sites: New Haven, Connecticut; Atlanta, Georgia; Grand Rapids, Michigan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Signal regulating proteins (SIRPs) participate in sarcoidosis granuloma formation by promoting immune cell aggregation.
Judson MA, Julian MW, Foulke L, et al. · Respir Res 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.